← Back to Search

Computerized Decision Support for Pulmonary Hypertension (CTEPH-DETECT Trial)

N/A
Waitlist Available
Led By Gregory Piazza, MD, MS
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether or not an electronic health record alert will increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in patients with prior pulmonary embolism and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms.

Who is the study for?
This trial is for adults who've had a pulmonary embolism, are experiencing symptoms like fatigue or chest pain, or have unexplained respiratory issues on tests. They haven't had an echocardiogram in the last 6 months and are seen at specific clinics.
What is being tested?
The study is testing if a computer alert for doctors increases screening and diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) in patients with past pulmonary embolisms showing certain symptoms.
What are the potential side effects?
Since this trial involves a computerized decision support system rather than medication, there are no direct side effects from interventions being tested.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency of echocardiographic screening for CTEPH in patients with prior PE and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3 months following randomization.
Secondary study objectives
Frequency of CTEPH diagnosis at three months.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AlertExperimental Treatment1 Intervention
On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
Group II: No AlertActive Control1 Intervention
No provider notification

Find a Location

Who is running the clinical trial?

BayerIndustry Sponsor
2,274 Previous Clinical Trials
25,531,999 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,666 Previous Clinical Trials
11,841,224 Total Patients Enrolled
Gregory Piazza, MD, MSPrincipal InvestigatorBWH
5 Previous Clinical Trials
12,970 Total Patients Enrolled
~60 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top